Log in

NASDAQ:CODX - Co-Diagnostics Stock Price, Forecast & News

$3.05
+0.04 (+1.33 %)
(As of 02/21/2020 02:35 AM ET)
Today's Range
$2.70
Now: $3.05
$3.30
50-Day Range
$0.91
MA: $2.15
$3.96
52-Week Range
$0.69
Now: $3.05
$4.24
Volume7.66 million shs
Average Volume7.60 million shs
Market Capitalization$65.85 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CODX
CUSIPN/A
Phone801-438-1036

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$40,000.00
Book Value($0.08) per share

Profitability

Net Income$-6,270,000.00
Net Margins-5,486.08%

Miscellaneous

Employees22
Market Cap$65.85 million
Next Earnings Date2/26/2020 (Estimated)
OptionableNot Optionable

Receive CODX News and Ratings via Email

Sign-up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.


Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions

What is Co-Diagnostics' stock symbol?

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics Inc (NASDAQ:CODX) announced its quarterly earnings data on Wednesday, November, 13th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.02. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.10 million. Co-Diagnostics had a negative return on equity of 202.74% and a negative net margin of 5,486.08%. View Co-Diagnostics' Earnings History.

When is Co-Diagnostics' next earnings date?

Co-Diagnostics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Co-Diagnostics.

What price target have analysts set for CODX?

2 equities research analysts have issued 1-year price targets for Co-Diagnostics' shares. Their forecasts range from $2.00 to $2.00. On average, they anticipate Co-Diagnostics' share price to reach $2.00 in the next year. This suggests that the stock has a possible downside of 34.4%. View Analyst Price Targets for Co-Diagnostics.

What is the consensus analysts' recommendation for Co-Diagnostics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Co-Diagnostics.

Has Co-Diagnostics been receiving favorable news coverage?

Headlines about CODX stock have trended somewhat positive on Friday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Co-Diagnostics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Co-Diagnostics.

Who are some of Co-Diagnostics' key competitors?

What other stocks do shareholders of Co-Diagnostics own?

Who are Co-Diagnostics' key executives?

Co-Diagnostics' management team includes the folowing people:
  • Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 66)
  • Dr. Brent C. Satterfield, Co-Founder, Chief Science Officer & Director (Age 42)
  • Mr. Reed L. Benson, CFO, Gen. Counsel & Sec. (Age 71)
  • Dr. Mayuranki Almaula, Sr. VP of Overseas Operations & Strategic Alliances
  • Mr. Cameron Gundry, Head of Commercialization LATAM/EUR

When did Co-Diagnostics IPO?

(CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO.

Who are Co-Diagnostics' major shareholders?

Co-Diagnostics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Barclays PLC (0.50%) and Virtu Financial LLC (0.22%). View Institutional Ownership Trends for Co-Diagnostics.

Which major investors are buying Co-Diagnostics stock?

CODX stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC and Barclays PLC. View Insider Buying and Selling for Co-Diagnostics.

How do I buy shares of Co-Diagnostics?

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Co-Diagnostics' stock price today?

One share of CODX stock can currently be purchased for approximately $3.05.

How big of a company is Co-Diagnostics?

Co-Diagnostics has a market capitalization of $65.85 million and generates $40,000.00 in revenue each year. Co-Diagnostics employs 22 workers across the globe.View Additional Information About Co-Diagnostics.

What is Co-Diagnostics' official website?

The official website for Co-Diagnostics is http://www.codiagnostics.com/.

How can I contact Co-Diagnostics?

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE - D, SALT LAKE CITY UT, 84109. The company can be reached via phone at 801-438-1036 or via email at [email protected]


MarketBeat Community Rating for Co-Diagnostics (NASDAQ CODX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  246 (Vote Underperform)
Total Votes:  466
MarketBeat's community ratings are surveys of what our community members think about Co-Diagnostics and other stocks. Vote "Outperform" if you believe CODX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CODX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel